Biomedical Advanced Research and Development Authority (BARDA) and CSL Seqirus will expand their reserves of MF59® adjuvant to the equivalent of 40 million doses as part of the National Pre-Pandemic ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

Vaccine maker CSL Seqirus has lined up yet another contract with the U.S. | With a $121.4 million award from the U.S.

SUMMIT, N.J., Oct. 1, 2024 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), today announced data from a range of real-world evidence (RWE) studies, highlighting the important role ...

SUMMIT, N.J., Oct. 1, 2024 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), today announced data from a range of real-world evidence (RWE) studies, highlighting the important role influenza ...

Today, CSL – including our three businesses: CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people.

SUMMIT, N.J., Sept. 25, 2024 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), announced today that through its public-private partnership with the Biomedical Advanced Research and ...

Biomedical Advanced Research and Development Authority (BARDA) and CSL Seqirus will expand their reserves of MF59® adjuvant to the equivalent of 40 million doses as part of the National Pre ...

It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus ...

"Once again, we're honored to partner with BARDA on pandemic preparedness," said Marc Lacey, CSL Seqirus, Global Executive Director for Pandemic. "This expanded program will increase outbreak ...